logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

MORSE Consulting Strengthens HTA Strategy and Payer Expertise

February 18, 2020
-
Market Access News, What's New
-
Posted by MORSE - 2 min read.

Toronto, February 18, 2020 – MORSE Consulting is pleased to expand and strengthen our service offering with the addition of Anita Carrie and Roy Cairns.

Affordability of effective and innovative medications within the current Canadian public funding model is becoming very challenging for the healthcare system.  Increasing budgetary constraints coupled with complex treatments requiring consideration of different sources and levels of evidence are an issue for all stakeholders. To help address this increasingly difficult environment, MORSE Consulting has bolstered its health technology assessment (HTA) and payer expertise.

We now offer HTA strategic advice through the addition of Anita Carrie, a senior consultant who has more than 20 years of experience working in multiple sectors including HTA,  hospital and consulting sectors. Most recently Anita served as a scientific advisor and research manager at Canadian Agency for Drugs and Technologies in Health (CADTH). During her time at CADTH Anita led or conducted the review of more than 100 single technology reviews, including communicating reimbursement recommendations of expert committees to public drug plans and other stakeholders. She is also a former practicing pharmacist, educator, and health services researcher experienced in conducting real world studies using administrative healthcare data.

Given the increasing linkages and coordination between different elements of the Canadian reimbursement pathway, it is imperative to understand the impact of HTA recommendations on payer negotiations and listing criteria.  Anita’s extensive CADTH experience, both as a scientific advisor and research manager, combined with MORSE’s public payer expertise will help our clients better understand and optimize their reimbursement planning and decision-making.

As a Senior Consultant, Anita is responsible for providing substantive guidance to clients related to MORSE’s reimbursement and health technology assessment strategy services.

 

 

MORSE Consulting is also pleased to further strengthen our public payer expertise through the addition of our new senior consultant, Roy Cairns.  He is a pharmacist with 35 years of experience and has represented a public payer at the assistant deputy minister (ADM), executive director, and operational levels and worked with federal/provincial/territorial governments, private insurers, pharmacy wholesalers, retail pharmacies, and pharmaceutical manufacturers.  Roy has represented a jurisdiction at the Canadian Agency for Drugs and Technologies in Health (CADTH), through both the oncology and non-oncology streams, as well as the pan-Canadian Pharmaceutical Alliance (pCPA) – at all levels including the Governing Council.  Roy has also participated in numerous national initiatives involving federal organizations (e.g. Health Canada, the Patented Medicine Prices Review Board) on topics such as National Pharmacare, Biologics/Biosimilars, and Expensive Drugs for Rare Diseases.

Beyond his understanding of regional issues, Roy’s involvement spans across jurisdictional, executive and operational frameworks that provides a unique perspective on how drug policy is developed and implemented in Canada.

As a Senior Consultant, Roy contributes to client success by providing public payer insights from numerous decision-making perspectives to better inform product positioning, pricing, reimbursement, and negotiation strategies.

 

 

The addition of Anita and Roy will further strengthen MORSE’s ability to provide clients with insightful strategies to help them effectively address Canada’s challenging and rapidly evolving reimbursement environment.

Please contact Arvind Mani (arvind@morseconsulting.ca) or Sherry O’Quinn (sherry@morseconsulting.ca) to learn more about how the MORSE team can help address your reimbursement needs.

 

Share
Tags
CADTH
CDR
DRD
Drugs For Rare Diseases
HTA
Market Access Strategy
MORSE Team
Negotiation Strategy
pCPA
pCPAO
Pharmacare
Pharmaceuticals
PLA
PLAs
PMPRB
Public Payers
Reimbursement strategy
Stakeholder strategy
← PREVIOUS POST
pCPA - The Beginning of a Period of Uncertainty?
NEXT POST →
pCPA Closing in on 300 Completed Negotiations

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
MORSE Consulting Strengthens HTA Strategy and Payer Expertise